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ABSTRACT 
Background:  Greater height and body mass index (BMI) have been associated with an increased risk of 
thyroid cancer, particularly papillary carcinoma, the most common and least aggressive subtype.  Few 
studies have evaluated these associations in relation to other, more aggressive histologic types or thyroid 
cancer-specific mortality. 
Methods: In this large pooled analysis of 22 prospective studies (833,176 men and 1,260,871 women), 
we investigated thyroid cancer incidence associated with greater height, body mass index (BMI) at 
baseline and young adulthood, and adulthood BMI gain (difference between young-adult and baseline 
BMI), overall and separately by sex and histological subtype using multivariable Cox proportional 
hazards regression models.  Associations with thyroid cancer mortality were investigated in a subset of 
cohorts (578,922 men and 774,373 women) that contributed cause of death information. 
Results: During follow-up, 2,996 incident thyroid cancers and 104 thyroid cancer deaths were identified.  
All anthropometric factors were positively associated with thyroid cancer incidence: HRs (95% CIs) for 
height (per 5 cm)=1.07 (1.04-1.10), BMI (per 5 kg/m2)=1.06 (1.02-1.10), waist circumference (per 5 
cm)=1.03 (1.01-1.05), young-adult BMI (per 5 kg/m2)=1.13 (1.02-1.25), and adulthood BMI gain (per 5 
kg/m2)=1.07 (1.00-1.15).  Associations for baseline BMI and waist circumference were attenuated after 
mutual adjustment.  Baseline BMI was more strongly associated with risk in men compared with women 
(P-interaction=0.04).  Positive associations were observed for papillary, follicular, and anaplastic, but not 
medullary, thyroid carcinomas. Similar, but stronger, associations were observed for thyroid cancer 
mortality.   
Conclusion:  Our results suggest that greater height and excess adiposity throughout adulthood are 
associated with higher incidence of most major types of thyroid cancer, including the least common but 
most aggressive form, anaplastic carcinoma, and higher thyroid cancer mortality. Potential underlying 
biological mechanisms should be explored in future studies. 
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INTRODUCTION 
Although thyroid cancer only accounts for approximately 2% of all cancers diagnosed worldwide (1), the 
incidence of thyroid cancer, particularly papillary thyroid carcinoma, has increased dramatically in many 
countries over the past few decades (2).  This pattern appears to reflect the enhanced ability to detect very 
small thyroid tumors, but some of the increase may be attributable to changes in the prevalence of 
lifestyle and environmental risk factors (3).  Exposure to ionizing radiation during childhood and 
adolescence, which is the only established modifiable risk factor, does not appear to have contributed 
importantly to these trends (4, 5).  Among other possible contributing factors includes the rising 
prevalence of obesity (6, 7). 
 
Greater body mass index (BMI), a measure of total adiposity, has been associated with an increased risk 
of thyroid cancer in several observational studies (6, 8-14), with some exceptions (15-18).  Most of these 
studies also showed positive associations with greater height.  While the underlying biological 
mechanisms remain speculative, studies utilizing other anthropometric measures or the same measures at 
different periods during life could provide additional clues.  Compared with BMI, waist circumference 
more directly measures the amount of central adipose tissue, the metabolic consequences of which 
include insulin resistance and inflammation (19).  However, associations of waist circumference with 
thyroid cancer risk have been examined in only three studies, with conflicting results (14, 15, 20).  BMI 
specifically in young adulthood has been associated with an increased risk of thyroid cancer in some 
studies (6, 10, 11, 15) but not others (8, 21).  Few studies have evaluated associations for specific 
histological subtypes apart from papillary carcinoma, which is the least aggressive and increasingly 
predominant subtype.   
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We compiled individual-level data from 22 prospective cohort studies from North America, Europe, 
Australia, and Asia to comprehensively evaluate height, baseline and young-adult BMI, adulthood BMI 
gain (difference between young-adult and baseline BMI), and waist circumference in relation to risk of 
thyroid cancer and major histologic subtypes.    
 
METHODS 
Study population 
Cohorts participating in the National Cancer Institute Cohort Consortium were eligible to join a pooled 
study of anthropometric factors and thyroid cancer risk if the baseline year occurred on or after 1970 and 
the study ascertained height and weight information (22-43).  Table 1 provides a brief description of the 
included cohorts and their acronyms.  Full cohort data were available from 20 cohorts.  CSDLH and 
NLCS used a case-cohort approach, providing data from all incident thyroid cancer cases and a random 
sample of participants from the full cohort.  Height and weight were self-reported in most cohorts, but 
measured in MCCS, SMHS, SWHS, most of EPIC (89%), and most of SISTER (>99%).  Information on 
waist circumference was ascertained in 15 cohorts (AARP, BCDDP, COSM, CPSII, CSDLH, CTS, EPIC, 
IWHS, MCCS, NYUWHS, SISTER, SMC, SMHS, SWHS, WLH), having been measured by someone 
other than the participant in six of these cohorts (EPIC (89%), MCCS, NYUWHS, SISTER, SMHS, 
SWHS), and data on young-adult weight (recalled for ages 17-21 by participants) was assessed in 10 of 
the cohorts (AARP, AHS, COSM, CPSII, IWHS, MCCS, PLCO, SMC, VITAL, WLH).  We calculated 
baseline and young-adult body mass index (BMI) as kg/m2.  BMI gain was defined as baseline BMI 
minus young-adult BMI.  Information on covariates, including education, marital status, alcohol 
consumption, smoking, physical activity level, and history of benign thyroid disease were self-reported.  
We formatted these data uniformly across studies using standard units and category cut-points prior to 
analysis.  Each study received approval from its respective institutional review board. 
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From a total of 2,281,345 eligible study participants, we excluded participants without follow-up time 
(n=19,953), whose age at study exit was implausible (>110 years) (n=65), who were younger than 18 or 
older than 85 years of age at baseline (n=7,286), who reported having had a previous diagnosis of cancer 
at baseline (n=102,116) as well as anyone with missing data on height or weight (n=55,703).  Participants 
with BMI values of less than 15 kg/m2 (n=1,717) and greater than or equal to 60 kg/m2 (n=458) were also 
excluded.  The final sample consisted of 2,094,047 individuals (833,176 men and 1,260,871 women) 
from 22 prospective cohort studies. 
 
Thyroid cancer follow-up  
Participants were followed baseline questionnaire completion date to any first primary cancer diagnosis 
other than non-melanoma skin cancer, loss-to-follow-up, death, or cohort-specific administrative end 
date, whichever occurred first.  Cancer diagnoses were identified through linkages to local, state, or 
national cancer registries (AARP, AHS, COSM, CSDLH, CTS, IWHS, MCCS, NLCS, SMC, WLH, 
VITAL), self-report verified through medical record confirmation (PHS, PLCO, SISTER, USRT, WHS), 
or a combination of approaches (BCDDP, CPSII, EPIC, NYUWHS, SMHS, SWHS).  Participants were 
classified as cases if the first primary cancer diagnosed during follow-up was malignant thyroid cancer 
(International Classification of Disease for Oncology, Third Edition [ICD-O-3], topography code C73 or 
the equivalent).  Histological subtypes of thyroid cancer were further classified using ICD-3 morphology 
codes or the equivalent (papillary: 8050, 8260, 8340-8344, 8350, 8450-8460; follicular: 8290, 8330-8335; 
medullary: 8345, 8510-8513; anaplastic: 8020-8035) (44).  
 
While not an original objective of the current study, we additionally evaluated anthropometric factors in 
relation to thyroid cancer mortality among the subset of the cohorts that additionally provided information 
on cause of death (AARP, AHS, BCDDP, COSM, CPSII, CTS, IWHS, MCCS, NYUWHS, PHS, PLCO, 
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SMC, USRT, VITAL, WHS, and WLH), including 1,353,295 study subjects (578,922 men and 774,373 
women).  Thyroid cancer deaths were defined using ICD-9 code 193 and ICD-10 code C73.   
 
 
Statistical analysis 
We estimated cohort- and sex-specific hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox 
proportional hazards regression models with attained age in years as the underlying time metric and 
adjusted for known or potential thyroid cancer risk factors, including race (White, Black, Asian, other), 
smoking status (never, former, current), education (high school or less, some college/post-high school 
training, college graduate), marital status (married/living together, divorced/separated, widowed, 
single/never married), physical activity level (cohort-specific tertiles), and alcohol intake (0-9, 10-19, 20+ 
grams of ethanol per day).  Data from the CSDLH and NLCS cohorts were analyzed separately using a 
case-cohort approach (45).  Between-study heterogeneity was evaluated using the I2 index, with a value of 
0% indicating none and higher values indicating increasing heterogeneity (46).  Full-cohort data from 20 
prospective studies were then aggregated to estimate pooled multivariable-adjusted HRs and 95% CIs in 
models additionally stratified by cohort, with anthropometric factors modeled categorically and 
continuously.  We found no evidence of non-linear relationships between any of the exposures examined 
in relation to thyroid cancer incidence or mortality based on restricted cubic spline models with automatic 
stepwise selection of up to four knots.  P-values for log-linear relationships were based on Wald tests 
corresponding to continuous values of the exposure.  The aggregate data were also used to evaluate effect 
modification, specifically by sex, geographical area, race/ethnicity, age at the time of report for height and 
weight, and age at thyroid cancer diagnosis, and smoking status, and to examine associations by 
histology.  We conducted interaction tests by comparing the fit of a model including a cross-product term 
between the exposure and effect modifier to one without using the likelihood ratio test.   To evaluate 
effect modification by age at diagnosis, we treated exposures as time-varying by splitting person-time for 
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each participant by category of attained age and evaluating the fit of a model with the cross-product term 
between exposure and attained age category to one without.  We observed no evidence of violation of the 
proportional hazards assumption.   
 
RESULTS 
A general description of the studies is shown in Table 1.  During an average 10.4 years of follow-up, we 
identified 2,996 first primary thyroid cancer cases (695 men and 2,301 women).  We classified 2,182 
(73%) as papillary, 418 (14%) as follicular, 100 (3%) as medullary, and 53 (2%) as anaplastic.  The mean 
age at baseline was 57 years and the mean age at thyroid cancer diagnosis during follow-up was 62 years 
(range: 25-92).   
 
In the subset of cohorts that contributed cause of death information, we identified 104 thyroid cancer 
deaths (53 men and 51 women).   
 
Study- and sex-specific HRs and 95% CIs for continuous values of height (per 5 cm increase), baseline 
BMI (per 5 kg/m2 increase), waist circumference (per 5 cm increase), young-adult BMI (per 5 kg/m2 
increase), and BMI gain (per 5 kg/m2 increase) are shown in Supplementary Figures 1-5.  Significant 
between-cohort differences were observed for the associations for baseline BMI (I2=41.1%) and young-
adult BMI in women (I2=59.0%) and waist circumference in men (I2=58.9%).  Heterogeity remained  
after individually excluding the two largest cohorts, AARP and EPIC.   
 
Pooled results 
In the aggregate dataset of 20 cohorts, increases in risk of thyroid cancer were observed for greater values 
(on a continuous scale, per 5 cm or 5 kg/m2) of height (HR=1.07, 95% CI: 1.04-1.10), baseline BMI 
(HR=1.06, 95% CI: 1.02-1.10), waist circumference (HR=1.03, 95% CI: 1.01-1.05), young-adult BMI 
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(HR=1.13, 95% CI: 1.02-1.25), and adulthood BMI gain (HR=1.07, 95% CI: 1.00-1.15) (Table 2).  The 
risk of thyroid cancer generally increased across categories of baseline height, BMI, and waist 
circumference, as well as young-adult BMI.  Adult BMI gain of 5.0-9.9 kg/m2 was associated with a 
statistically significant 23% increased risk (95% CI: 6-42%) compared with a BMI gain of 0-4.9 kg/m2, 
but the  risk for a BMI gain of ≥10 kg/m2 was not significantly different from unity.  Positive associations 
for height, baseline BMI, waist circumference, and young-adult BMI were observed in both men and 
women.  The association for baseline BMI was significantly stronger for men versus women (P-
interaction=0.04). The association for adulthood BMI gain was restricted to men (HR for men=1.23, 95% 
CI: 1.07-1.41), but not significantly modified by sex (P-interaction=0.12).   
 
The HRs for BMI (per 5 kg/m2 increase) were attenuated after restricting the analysis to subjects with 
measured values, although the sample size was substantially reduced (based on 743 cases, HR=1.01, 95% 
CI: 0.93-1.10); this attenuation was restricted to men (HR=0.76, 95% CI: 0.57-1.03; HR for women=1.03, 
95% CI: 0.95-1.13).  The HRs for height (per 5 cm) did not materially change (data not shown).  As 
observed previously (14), the HRs for height and BMI in EPIC did not materially change after excluding 
self-reported values (data not shown).  Adjusting for history of benign thyroid conditions from the subset 
of studies with this information yielded similar results (data not shown).  HRs and 95% CIs for height in 
models unadjusted for BMI were similar to adjusted models in the overall study population, in men, and 
in women: 1.07 (1.04-1.10), 1.05 (0.99-1.11) and 1.07 (1.04-1.11), respectively. 
 
HRs for waist circumference (per 5 cm increase) and BMI (per 5 kg/m2 increase) were both attenuated 
after mutual adjustment (HR for waist=1.02, 95% CI: 0.98-1.06; HR for BMI=1.01, 95% CI 0.92-1.12); 
similar findings were observed by sex (data not shown).  No consistent pattern in the association between 
waist circumference (per 5 cm increase) and thyroid cancer was observed in models stratified by baseline 
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BMI: HRs (95% CIs) for BMI <25.0, 25.0-29.9, and ≥30 kg/m2 were 1.01 (0.96-1.07), 1.05 (0.99-1.12), 
and 1.02 (0.96-1.08), respectively. 
 
Results from models of waist-to-hip ratio, available for 50.7% of the entire sample, suggested a non-
significant linear association with thyroid cancer risk (data not shown in tables).  The HRs (95% CIs) per 
0.1 difference were 1.05 (0.97-1.14) overall, 1.06 (0.88-1.28) for men, and 1.05 (0.96-1.14) for women.  
These results are consistent with results from models of waist circumference.   
 
We found that the positive association for adulthood BMI gain (per 5 kg/m2) was restricted to participants 
whose young-adult BMI was 18.5-22.4 (HR=1.16, 95% CI: 1.05-1.29).  HRs (95% CIs) per 5 kg/m2 of 
BMI gain within the categories of young-adult BMI <18.5, 22.5-24.9, and ≥25 kg/m2 were 0.95 (0.76-
1.19), 1.02 (0.86-1.21), and 0.99 (0.84-1.16), respectively. 
 
Differences by demographic factors and smoking status.  Significant differences were observed for the 
association of height and thyroid cancer risk by race (stronger for Blacks and Asians), baseline age 
(stronger for younger ages), and age at thyroid cancer diagnosis (stronger for younger ages) 
(Supplementary Table 1).  Other differences observed, although not statistically significant, including 
stronger associations for baseline and young-adult BMI and BMI gain among individuals who were older 
at baseline, stronger associations for waist circumference in U.S.-based studies and in Whites, and 
stronger associations for BMI gain in Asians than Whites or Blacks and never smokers (Supplementary 
Table 1).  In women, no significant differences were observed by age at thyroid cancer diagnosis (before 
versus after age 55, a proxy for age at menopause; data not shown).   
 
Differences by histology.  Significant positive associations were observed for papillary carcinoma with 
height and young-adult BMI, follicular carcinoma with height and baseline BMI, and anaplastic 
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carcinoma with baseline BMI and BMI gain in adulthood (Table 3).  Inverse associations for baseline 
BMI, waist circumference, and BMI gain with risk of medullary carcinoma did not materially change 
after excluding the first two years of follow-up (data not shown).  Sex modified some of the histology-
specific associations.  Papillary carcinoma was associated with baseline BMI only in men and height only 
in women, but these differences were not statistically significant (P-interactions=0.08 and 0.47, 
respectively).  Inverse associations for medullary carcinoma with baseline BMI, waist circumference, and 
BMI gain were observed only in women, but this sex difference was significant only for baseline BMI (P-
interactions=0.02, 0.30, 0.27, respectively).  The association for baseline BMI and anaplastic thyroid 
cancer was stronger in women versus men (P-interaction=0.03).  However, the results for medullary and 
anaplastic thyroid cancer were based on relatively few cases (no more than 92 and 42, respectively, in any 
given model). 
 
Thyroid cancer mortality.  We found that greater height, baseline BMI, waist circumference, young-adult 
BMI, and adulthood BMI gain were associated with increased risk of thyroid cancer mortality; results 
from continuous models (per 5-unit increases) of baseline BMI (HR=1.29, 95% CI: 1.07-1.55), waist 
circumference (HR=1.22, 95% CI: 1.10-1.36), and young-adult BMI (HR=1.56, 95% CI: 1.13-2.15) were 
statistically significant (Supplementary Table 2).  The patterns in risk overall and by sex were similar to 
those observed for thyroid cancer incidence, but the associations were generally stronger in magnitude.  
No significant differences were observed by sex. 
 
DISCUSSION 
In this comprehensive pooled analysis of 22 prospective cohort studies from North America, Europe, and 
Asia, we found that height, baseline BMI, waist circumference, young-adult BMI, and adulthood BMI 
gain were each positively associated with incidence of total thyroid cancer.  These associations were 
independent of smoking and other factors associated with thyroid cancer risk.  The association for 
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baseline BMI was stronger in men compared with women.  Some other differences in risk by population 
subgroup were observed (e.g., stronger associations for baseline BMI in U.S. studies and in whites).  Risk 
patterns were similar for papillary, follicular, and anaplastic carcinoma.  None of the anthropometric 
factors examined were associated with risk of medullary carcinoma, but the confidence intervals were 
wide.  These associations were stronger in magnitude for thyroid cancer mortality compared with 
incidence. 
Compared to most other cancer sites, the associations we observed for height (per 5 cm increase) and 
BMI (per 5 kg/m2 increase) with incidence of total, papillary, and follicular thyroid cancer were similar in 
magnitude (47-50).  However, the associations of BMI with anaplastic thyroid cancer in women 
(HR=1.66) and thyroid cancer mortality in men (HR=1.47) and men and women combined (HR=1.29) 
were stronger and more comparable with cancers that have consistently been linked with obesity, 
including esophageal adenocarcinoma and endometrial and kidney cancers (50). 
Few observational studies have collected information on anthropometric measures other than height and 
weight.  BMI is a widely-used measure of adiposity but provides no information on the amount of lean 
versus fat mass or central versus peripheral body fat (51).  Waist circumference and weight gain are more 
direct measures of central (visceral) adiposity and body fat mass, respectively.  In the current study, we 
found positive associations for waist circumference (but not independent of baseline BMI), young-adult 
BMI, and adulthood BMI gain with thyroid cancer risk.  These results suggest an important role of excess 
total (as opposed to central) adiposity across the lifespan on thyroid cancer incidence.  Prospective studies 
that directly evaluate pre-diagnostic levels of biomarkers of insulin resistance, inflammation, estrogen, 
and other metabolic disturbances related to total adiposity may provide some insight regarding possible 
underlying mechanisms (52-54).   
While the likelihood of thyroid nodule detection and thyroid cancer diagnosis could conceivably be 
greater for individuals with an underlying thyroid condition, our results did not change after adjusting for 
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a history of benign thyroid conditions.  In cross-sectional studies, a greater BMI has been associated with 
higher thyroid cancer prevalence among individuals with screen-detected thyroid nodules (55) and 
increased tumor aggressiveness among overweight and obese papillary thyroid cancer patients (56, 57).  
In a previous case-control study, greater BMI was associated with risk of thyroid cancers less than and 
greater than 10 mm in size (9).  Taken together, these observations suggest that surveillance biases do not 
fully account for associations observed between excess adiposity and thyroid cancer in this and other 
studies. 
Consistent with most previous studies, adult height was positively associated with thyroid cancer risk in 
both men and women.  Taller height in adolescence has also been associated with risk of thyroid cancer in 
adulthood (58).  This relationship could be explained by higher circulating levels of insulin-like growth 
factor-I (IGF-I) in taller individuals (59).  A higher serum concentration of IGF-I was associated with 
increased risk of differentiated thyroid cancer in the European Investigation into Cancer and Nutrition 
cohort (60).  Other potential explanations for the positive association for height include the larger size of 
the thyroid gland (and, thus, greater number of cells with the potential to undergo malignant 
transformation) and greater likelihood of nodule detection via palpation. 
 
Due to relatively small sample sizes, very few previous studies have shown associations between 
anthropometric factors and risk of specific histological sub-types of thyroid cancer apart from papillary 
thyroid carcinoma, the most common form of the disease.  A previous large prospective study in Norway 
showed that baseline BMI was positively associated with risk of total thyroid cancer and papillary, 
follicular, and anaplastic sub-types and an inverse association with medullary thyroid cancer (12).  An 
inverse association between BMI and medullary thyroid cancer risk was also reported in a pooled analysis 
of 14 case-control studies (67 cases) (61).  Also consistent with our results, the Norwegian study showed 
a stronger association of BMI with follicular and anaplastic compared with papillary thyroid cancer (12).   
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The incidence of papillary thyroid cancer has increased dramatically in several countries over the past 
three to four decades (2).  The rising prevalence of obesity in these countries has been proposed as one 
potential explanation (6).  While our results are consistent with this hypothesis, they also suggest that the 
strength of this association is relatively weak, particularly for women.  Several other factors influence 
thyroid cancer incidence trends, including changing clinical practices with regard to screening and 
diagnosis and changing prevalence of other thyroid cancer risk factors.  Based on results from the current 
study, we would expect that increasing rates of obesity would, if anything, have a weak impact on 
population-level changes in papillary thyroid cancer incidence. 
 
Overall, our results suggest that greater adiposity and taller height are associated with increased risk of 
thyroid tumors that arise from the follicular, but not parafollicular, cells of the thyroid (62).  Excess 
weight and weight gain may be particularly important for risk of more aggressive tumors, as suggested by 
the relatively strong associations we observed for BMI and BMI gain with anaplastic thyroid cancer and 
thyroid cancer mortality.  This hypothesis is supported by a recent study examining the effect of an 
obesity-inducing high-fat diet on thyroid carcinogenesis using a ThrbPV/PV/Pten+/- mouse model, which 
found that such a diet increased thyroid tumor cell proliferation and induced anaplastic changes, as well 
as increased serum leptin levels (63).  Although anaplastic thyroid cancer is uncommon, median survival 
after diagnosis is low; thus, improving our understanding of the etiology of this malignancy is particularly 
important. 
 
Major strengths of this pooled analysis include the prospective study design, wide variability in the 
included studies, and the large sample size which allowed for a detailed investigation by race, smoking, 
geography, baseline age, and age at diagnosis, as well as histology.  To the best of our knowledge, this is 
the first study evaluating the association between anthropometric factors and thyroid cancer mortality.  
All of the included studies collected information on potential confounders, including education, smoking, 
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alcohol intake, physical activity, which allowed us to control for these possible sources of confounding 
using a standardized approach.   
 
Limitations of our study include the use of mostly self-reported, as opposed to measured, anthropometric 
factors, and the lack of information on body weight during follow-up.  However, measurement error was 
most likely non-differential by case status, which would have attenuated the associations.  We lacked 
information on thyroid tumor size, which could have helped distinguish smaller, less aggressive thyroid 
cancers from those that are clinically relevant.  However, we found, in the subset of cohorts for which we 
received cause of death information, stronger associations for height and excess weight with thyroid 
cancer mortality compared with incidence.  These results suggest that biological factors related to taller 
height and greater adiposity at baseline (generally mid-to-older adulthood) and young adulthood influence 
the development of more aggressive forms of thyroid cancer.  Despite the large sample size, some of our 
results, particularly in subgroup analyses, may be due to chance.  While the large number of studies 
contributing to our pooled analysis allowed for an evaluation of the consistency of the associations across 
different study populations, our results should be interpreted cautiously and in consideration of the 
difference in the range of values of the anthropometric factors across populations and the between-study 
heterogeneity observed for some factors. 
 
In summary, greater height, excess weight early in life, and, among men, excess weight in mid-to-older 
adulthood were associated with increased incidence of total thyroid cancer and most major thyroid cancer 
subtypes, including anaplastic thyroid cancer.  Baseline BMI and waist circumference and young-
adulthood BMI were more strongly associated with thyroid cancer mortality compared with incidence, 
providing further support that these factors influence risk of more aggressive or clinically-relevant forms 
of thyroid cancer.  Future research is needed to understand the possible underlying biological 
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mechanisms.  More broadly, our results support efforts to achieve and maintain a healthy weight 
throughout life to minimize risks of cancer and other major chronic diseases.   
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Table 1.  Description of the studies included in the pooled analysis of anthropometric factors and thyroid cancer risk 
 
Cohort name Cohort 
acronym 
Geographic 
location 
Study design Participants Thyroid cancer 
cases 
Study 
period 
Years of follow-up, 
mean (SD) 
Age at baseline, 
mean (SD) 
Baseline BMI 
≥30 (%) 
    Men Women Men Women     
NIH-AARP Diet and Health Study 22) AARP U.S. Cohort 304,592 195,251 260 327 1995-2006 9.1 (2.9) 62.0 (5.4) 22 
Agricultural Health Study (23) AHS U.S. Cohort 38,383 27,458 33 55 1993-2008 12.7 (2.5) 47.2 (12.4) 22 
Breast Cancer Detection Demonstration Project 
(24) 
BCDDP U.S. Cohort ---- 38,140 ---- 35 1987-1997 8.2 (1.7) 61.7 (8.0) 13 
Cohort of Swedish Men (25) COSM Sweden Cohort 43,500 ---- 21 ---- 1998-2008 9.3 (2.5) 60.6 (9.7) 10 
Cancer Prevention Study-II (26) CPSII U.S. Cohort 72,589 80,997 87 129 1992-2009 12.2 (3.9) 63.0 (6.4) 15 
Canadian Study of Diet, Lifestyle, and Healtha (27) CSDLH Canada Case-cohort 4,100 4,268 23 73 1991-2010 9.9 (4.9) 61.2 (13.1) 10 
California Teachers Study (28) CTS U.S. Cohort ---- 104,442 ---- 277 1995-2010 12.9 (4.0) 51.9 (13.5) 14 
European Prospective Investigation Into Cancer 
and Nutrition (29) 
EPIC Europe  
(multiple sites) 
Cohort 146,430 341,073 67 540 1991-2010 11.0 (2.8) 51.3 (9.9) 14 
Iowa Women’s Health Study (30) IWHS U.S. Cohort ---- 37,957 ---- 67 1986-2005 16.4 (5.5) 62.2 (4.2) 19 
Melbourne Collaborative Cohort Study (31) MCCS Australia Cohort 15,687 22,335 12 35 1990-2009 14.9 (4.1) 55.1 (8.7) 21 
Netherlands Cohort Studyb (32) NLCS Netherlands Case-cohort 2,269 2,389 23 52 1986-2003 14.9 (4.3) 61.4 (4.2) 7 
New York University Women’s Health Study (33) NYUWHS U.S. Cohort ---- 13,306 ---- 48 1985-2007 18.7 (5.2) 50.6 (8.7) 13 
Physicians’ Health Study (34) PHS U.S. Cohort 28,350 ---- 51 ---- 1981-2009 18.1 (8.4) 55.3 (9.7) 6 
Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Study (35) 
PLCO U.S. Cohort 71,068 69,990 50 93 1993-2006 8.4 (2.8) 63.1 (5.4) 24 
Sister Study (36) SISTER U.S. Cohort ---- 48,167 ---- 81 2003-2012 3.7 (1.3) 55.5 (9.0) 30 
Swedish Mammography Cohort (37) SMC Sweden Cohort ---- 36,375 ---- 16 1998-2008 9.7 (2.1) 62.3 (9.2) 11 
Shanghai Men’s Health Study (38) SMHS China Cohort 61,394 ---- 26 ---- 2001-2009 5.4 (1.4) 55.4 (9.7) 3 
Shanghai Women’s Health Study (39) SWHS China Cohort ---- 74,861 ---- 163 1996-2009 10.8 (1.9) 52.6 (9.1) 5 
U.S. Radiologic Technologists Study (40) USRT U.S. Cohort 13,317 49,395 19 119 1994-2006 8.9 (1.5) 47.9 (8.5) 16 
VITamins and Lifestyle Study (41) VITAL U.S. Cohort 31,497 31,310 23 69 2000-2009 7.4 (2.0) 60.9 (7.3) 25 
Women’s Health Study (42) WHS U.S. Cohort ---- 38,946 ---- 101 1993-2010 14.7 (3.9) 54.7 (7.0) 18 
Swedish Women’s Lifestyle and Health Study (43) WLH Sweden Cohort ---- 44,211 ---- 21 1991-2006 14.8 (1.7) 40.2 (5.8) 6 
Overall    833,176 1,260,871 695 2,301 1981-2012 10.4 (4.0) 56.7 (10.3) 17 
 
a Subcohort selected from a full cohort of 34,291 men and 39,618 women 
b Subcohort selected from a full cohort of 58,279 men and 62,573 women 
 
 
Table 2.  Hazard ratios (HRs) and 95% confidence intervals (CIs) for thyroid cancer according to anthropometric factors 
 Men  Women Total  
  No. cases HRa 95% CI  No. cases HRa 95% CI  No. cases HRa 95% CI  
Height (cm)b,c             
M 122-169/W 122-149 67 0.87 0.64-1.18  32 0.73 0.50-1.07  99 0.79 0.63-1.00  
M 170-174/W 150-154 119 1.00 Reference  174 1.00 Reference  305 1.00 Reference  
M 175-179/W 155-159 192 1.18 0.94-1.48  335 1.23 1.03-1.48  557 1.21 1.05-1.40  
M 180-184/W 160-164 158 1.07 0.84-1.37  564 1.21 1.02-1.44  790 1.20 1.05-1.37  
M 185-189/W 165-169 68 1.02 0.76-1.39  488 1.24 1.04-1.48  598 1.19 1.03-1.38  
M 190-244/W 170-244 35 1.35 0.92-1.98  388 1.41 1.17-1.69  452 1.38 1.18-1.61  
Per 5 cm 639 1.05 1.00-1.11  1,981 1.08 1.04-1.12  2,801 1.07 1.04-1.10  
Baseline BMI (kg/m2)d             
15.0-18.4 2 0.66 0.16-2.67  29 0.86 0.59-1.24  32 0.78 0.55-1.10  
18.5-24.9 191 1.00 Reference  995 1.00 Reference  1,313 1.00 Reference  
25.0-29.9 327 1.23 1.02-1.47  615 1.02 0.93-1.14  980 1.05 0.96-1.14  
30.0-59.9 129 1.35 1.07-1.71  356 1.05 0.92-1.19  500 1.09 0.98-1.22  
Per 5 kg/m2 649 1.17g 1.06-1.28  1,995 1.04g 1.00-1.09  2,825 1.06 1.02-1.10  
Waist circumference (cm)e             
M 52-79/W 52-69 15 1.31 0.73-2.36  185 0.97 0.80-1.16  200 0.99 0.84-1.18  
M 80-89/W 70-79 59 1.00 Reference  357 1.00 Reference  416 1.00 Reference  
M 90-99/W 80-89 114 1.18 0.85-1.62  292 1.06 0.91-1.24  406 1.08 0.94-1.24  
M 100-109/W 90-99 70 1.26 0.88-1.81  171 1.25 1.04-1.51  243 1.25 1.06-1.48  
M 110-189/W100-189 37 1.50 0.98-2.30  94 1.13 0.90-1.44  132 1.22 1.00-1.49  
Per 5 cm 295 1.04 0.98-1.10  1,099 1.02 1.00-1.05  1,397 1.03 1.01-1.05  
Young-adult BMI (kg/m2)d             
15.0-18.4 32 1.04 0.71-1.52  113 1.21 0.98-1.50  145 1.17 0.97-1.40  
18.5-22.4 159 1.00 Reference  360 1.00 Reference  519 1.00 Reference  
22.5-24.9 96 1.28 0.99-1.65  82 1.01 0.79-1.28  178 1.13 0.95-1.34  
25.0-59.9 66 1.34 1.00-1.80  62 1.50 1.14-1.96  128 1.40 1.15-1.70  
Per 5 kg/m2 353 1.18 1.01-1.40  617 1.10 0.96-1.25  970 1.13 1.02-1.25  
Adulthood BMI gain (kg/m2)f             
<0 20 0.79 0.49-1.29  56 1.11 0.82-1.50  76 1.01 0.79-1.30  
0-4.9 156 1.00 Reference  245 1.00 Reference  401 1.00 Reference  
5.0-9.9 143 1.30 1.03-1.65  223 1.20 1.00-1.44  366 1.23 1.06-1.42  
≥10.0 34 1.27 0.86-1.86  93 1.09 0.85-1.39  127 1.13 0.92-1.39  
Per 5 kg/m2 353 1.23 1.07-1.41  617 1.02 0.94-1.11  970 1.07 1.00-1.15  
Bolded: P-value <0.05 
a Adjusted for age (used as time metric), sex, alcohol intake, physical activity level, race, marital status, education, and smoking status and stratified by cohort 
b Additionally adjusted for baseline BMI (per 5 kg/m2) 
c Restricted to height values between 122-244 cm 
d Restricted to BMI values between 15.0-59.9 kg/m2 
e Restricted to waist circumference values between 52-189 cm 
f Additionally adjusted for young-adult BMI (per 5 kg/m2)  
g P-interaction (by sex)= 0.04 
Table 3.  Sex-specific hazard ratios (HRs) and 95% confidence intervals (CIs) for thyroid cancer and histological subtypes according to 
anthropometric factors 
  Papillary   Follicular  Medullary  Anaplastic 
  No. cases HRa 95% CI   No. cases HRa 95% CI  No. cases HRa 95% CI  No. cases HRa 95% CI 
Men                  
Height (per 5 cm)b,c  396 1.02 0.95-1.10   131 1.09 0.97-1.23  29 1.16 0.90-1.50  19 1.11 0.81-1.51 
Baseline BMI (per 5 kg/m2)d  402 1.15 1.02-1.29   132 1.17 0.95-1.44  31 1.25g 0.80-1.93  19 0.85h 0.45-1.63
Waist circumference (per 5cm)e  198 1.04 0.97-1.11   62 1.02 0.90-1.15  12 0.99 0.74-1.32  7 0.80 0.53-1.20 
Young-adult BMI (per 5 kg/m2)d  238 1.27 1.05-1.54   81 0.90 0.61-1.31  12 1.17 0.47-2.94  12 1.33 0.56-3.17 
Adulthood BMI gain (per 5 kg/m2)f  238 1.24 1.05-1.46   81 1.24 0.92-1.66  12 0.97 0.43-2.22  12 1.12 0.51-2.46 
                  
Women                  
Height (per 5 cm)b,c  1,663 1.08 1.04-1.12   248 1.15 1.04-1.26  61 0.95 0.78-1.16  23 1.21 0.89-1.66 
Baseline BMI (per 5 kg/m2)d  1,676 1.01 0.96-1.06   249 1.13 1.00-1.28  61 0.65g 0.47-0.91  23 1.66h 1.23-2.23 
Waist circumference (per 5cm)e  802 1.01 0.98-1.04   139 1.07 1.00-1.15  35 0.84 0.71-0.99  9 1.22 0.96-1.56 
Young-adult BMI (per 5 kg/m2)d  481 1.10 0.95-1.27   100 1.15 0.84-1.59  16 0.58 0.20-1.70  7 1.43 0.51-4.04 
Adulthood BMI gain (per 5 kg/m2)f  481 1.03 0.94-1.14   100 1.01 0.81-1.25  16 0.41 0.19-0.86  7 2.13 1.20-3.78 
                  
Totali                  
Height (per 5 cm)b,c  2,059 1.07 1.03-1.10   379 1.13 1.04-1.21  90 1.02 0.87-1.20  42 1.17 0.94-1.46 
Baseline BMI (per 5 kg/m2)d  2,078 1.03 0.98-1.08   381 1.14 1.02-1.26  92 0.80 0.62-1.03  42 1.43 1.09-1.89 
Waist circumference (per 5cm)e  1,000 1.01 0.98-1.04   201 1.06 1.00-1.13  47 0.87 0.76-1.01  16 1.07 0.86-1.32 
Young-adult BMI (per 5 kg/m2)d  719 1.16 1.03-1.30   181 1.03 0.80-1.32  28 0.86 0.44-1.69  19 1.38 0.71-2.67 
Adulthood BMI gain (per 5 kg/m2)f  719 1.08 0.99-1.17   181 1.09 0.92-1.30  28 0.59 0.34-1.00  19 1.60 1.01-2.54 
Bolded: P-value <0.05 
a Adjusted for age (used as time metric), alcohol intake (0-9, 10-19, 20+ grams of ethanol per day), physical activity level (cohort-specific tertiles), race (White, 
Black, Asian, other), marital status (married/living together, divorced/separated, widowed, single/never married), education (high school or less, some 
college/post-high school training, college graduate), and smoking status (never, former, current) and stratified by cohort 
b Additionally adjusted for baseline BMI (per 5 kg/m2) 
c Restricted to height values between 122-244 cm 
d Restricted to BMI values between 15.0-59.9 kg/m2 
e Restricted to waist circumference values between 52-189 cm 
f Additionally adjusted for young-adult BMI (per 5 kg/m2)  
g P-interaction (by sex)= 0.02 
h P-interaction (by sex)= 0.03 
i Additionally adjusted for sex 
 
 
 
 
 
Supplementary Table 1.  Hazard ratios (HRs) and 95% confidence intervals (CIs) for thyroid cancer by demographic factors and smoking status 
 
  Height (per 5 cm)   Baseline BMI (per 5 kg/m2)  Waist circumference (per 5 cm)  Young-adult BMI (per 5 kg/m2)  Adulthood BMI gain (per 5 kg/m2) 
  No. cases HRa 95% CI   No. cases HRa 95% CI  No. cases HRa 95% CI  No. cases HRa 95% CI  No. cases HRa 95% CI 
Geographical area                      
U.S.  1,902 1.07 1.03-1.10b   1,924 1.09 1.04-1.14b  733 1.05 1.02-1.08b  877 1.13 1.01-1.26  877 1.08 1.00-1.17 
Europe  810 1.06 1.00-1.11   834 1.03 0.95-1.11  508 1.03 0.99-1.07  110 1.15 0.86-1.54  110 0.94 0.72-1.21 
China  189 1.24 1.08-1.42   189 0.80 0.64-1.01  189 0.91 0.83-0.99  --- --- ---  --- --- --- 
Australia  47 0.99 0.79-1.24   47 1.15 0.86-1.55  47 1.01 0.88-1.14  46 1.20 0.76-1.89  46 1.06 0.75-1.49 
Race                      
White  2,466 1.06 1.03-1.10b   2,490 1.07 1.03-1.12  1,155 1.04 1.01-1.06b  928 1.13 1.01-1.25  928 1.07 1.00-1.16 
Black  46 1.22 1.04-1.43   46 0.88 0.66-1.17  13 1.01 0.82-1.23  21 1.03 0.54-1.96  21 0.83 0.52-1.31 
Asian  220 1.23 1.09-1.39   220 0.90 0.74-1.11  197 0.91 0.83-0.99  11 1.29 0.44-3.76  11 2.69 1.43-5.04 
Baseline age                      
<50  846 1.08 1.02-1.14b   858 1.05 0.97-1.13  438 1.04 1.00-1.08  71 0.93 0.63-1.38  71 1.10 0.81-1.51 
50-59  1,013 1.08 1.03-1.14   1,022 1.04 0.97-1.10  482 1.03 0.99-1.07  379 1.12 0.95-1.31  379 1.00 0.90-1.12 
60+  942 1.06 1.01-1.11   945 1.09 1.02-1.17  477 1.03 0.99-1.07  520 1.16 1.01-1.33  520 1.13 1.02-1.25 
Age at diagnosis/ 
study exit 
                     
<50  372 1.10 1.01-1.19b   379 1.04 0.93-1.15  179 1.04 0.98-1.11  100 1.03 0.76-1.39  100 1.15 0.90-1.47 
50-59  794 1.05 1.00-1.11   801 1.03 0.95-1.11  384 1.01 0.96-1.05  187 1.18 0.95-1.46  187 1.01 0.86-1.19 
60-69  1,018 1.08 1.03-1.14   1,025 1.06 0.99-1.13  436 1.03 0.99-1.07  435 1.11 0.95-1.29  435 1.06 0.95-1.17 
70+  617 1.05 0.99-1.11   620 1.11 1.02-1.21  252 1.03 0.97-1.09  379 1.13 0.95-1.34  379 1.13 1.00-1.27 
Smoking status                      
Never  1,578 1.08 1.04-1.13   1,594 1.06 1.00-1.11  810 1.03 0.99-1.06  480 1.10 0.94-1.28  480 1.12 1.02-1.24 
Former  900 1.04  0.99-1.09   905 1.05 0.98-1.12  410 1.02 0.98-1.06  398 1.12 0.96-1.31  398 1.02 0.90-1.14 
Current  259 1.14 1.04-1.25   262 1.04 0.90-1.20  157 1.03 0.96-1.11  72 1.11 0.78-1.58  72 0.94 0.71-1.26 
Bolded= P-value <0.05 (Wald test) 
a Adjusted for age (used as time metric), sex, alcohol intake, physical activity level, race, marital status, education, and smoking status and stratified by cohort 
b P-interaction <0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2.  Hazard ratios (HRs) and 95% confidence intervals (CIs) for thyroid cancer mortality according to anthropometric factors 
 Men  Women Total  
  No. cases HRa 95% CI  No. cases HRa 95% CI  No. cases HRa 95% CI  
Height (cm)b,c             
M 122-169/W 122-149 5 0.87 0.30-2.51  2 1.57 0.30-8.19  7 0.97 0.40-2.39  
M 170-174/W 150-154  11 1.00 Reference  5 1.00 Reference  16 1.00 Reference  
M 175-179/W 155-159 11 0.68 0.29-1.57  5 0.80 0.23-2.78  16 0.72 0.36-1.44  
M 180-184/W 160-164 19 1.31 0.62-2.77  15 1.20 0.43-3.36  34 1.21 0.66-2.22  
M 185-189/W 165-169 5 0.77 0.27-2.23  13 1.23 0.43-3.36  18 0.99 0.49-1.98  
M 190-244/W 170-244 2 0.82 0.18-3.73  11 1.63 0.55-4.85  13 1.30 0.60-2.79  
Per 5 cm 53 1.05 0.87-1.27  51 1.26 1.04-1.54  104 1.14 1.00-1.31  
Baseline BMI (kg/m2)d             
15.0-18.4 0  n.e  1 2.02 0.27-15.37  1 1.43 0.19-10.51  
18.5-24.9 15 1.00 Reference  15 1.00 Reference  30 1.00 Reference  
25.0-29.9 18 0.83 0.41-1.67  17 1.50 0.74-3.03  35 1.09 0.66-1.80  
30.0-59.9 20 2.43 1.19-4.99  18 2.72 1.33-5.56  38 2.55 1.54-4.22  
Per 5 kg/m2 53 1.47 1.10-1.96  51 1.20 0.93-1.54  104 1.29 1.07-1.55  
Waist circumference (cm)e             
M 52-79/W 52-69 1  n.e  4 1.28 0.27-6.00  5 2.16 0.48-9.70  
M 80-89/W 70-79 0 1.00 Reference  3 1.00 Reference  3 1.00 Reference  
M 90-99/W 80-89 7  n.e  8 3.39 0.89-12.95  15 4.59 1.31-16.11  
M 100-109/W 90-99 7  n.e  7 5.52 1.37-22.29  14 7.62 2.12-27.35  
M 110-189/W100-189 4  n.e  4 5.71 1.19-27.46  8 8.60 2.18-33.86  
Per 5 cm 19 1.19 0.99-1.44  26 1.24 1.08-1.41  45 1.22 1.10-1.36  
Young-adult BMI (kg/m2)d             
15.0-18.4 4 2.53 0.76-8.45  4 0.88 0.30-2.63  8 1.37 0.61-3.04  
18.5-22.4 8 1.00 Reference  17 1.00 Reference  25 1.00 Reference  
22.5-24.9 9 2.45 0.94-6.40  3 0.77 0.22-2.62  12 1.45 0.72-2.91  
25.0-59.9 12 5.04 2.03-12.50  5 2.60 0.95-7.13  17 3.54 1.88-6.66  
Per 5 kg/m2 33 1.76 1.19-2.61  29 1.30 0.74-2.27  62 1.56 1.13-2.15  
Adulthood BMI gain (kg/m2)f             
<0 2 0.47 0.10-2.27  5 2.69 0.80-9.05  7 1.22 0.49-3.00  
0-4.9 16 1.00 Reference  7 1.00 Reference  23 1.00 Reference  
5.0-9.9 9 0.84 0.37-1.94  11 1.96 0.75-5.10  20 1.15 0.63-2.12  
≥10.0 6 2.15 0.81-5.72  6 2.47 0.81-7.55  12 1.95 0.94-4.04  
Per 5 kg/m2 33 1.43 0.97-2.11  29 1.16 0.80-1.68  62 1.23 0.94-1.60  
Bolded: P-value <0.05 
a Adjusted for age (used as time metric), sex, alcohol intake, physical activity level, race, marital status, education, and smoking status and stratified by cohort 
b Additionally adjusted for baseline BMI (per 5 kg/m2) 
c Restricted to height values between 122-244 cm 
d Restricted to BMI values between 15.0-59.9 kg/m2 
e Restricted to waist circumference values between 52-189 cm 
f Additionally adjusted for young-adult BMI (per 5 kg/m2)  
 
 
 
Supplementary Figure 1.  Hazard ratios (HRs)a,b and 95% confidence intervals (CIs) for a 5 cm increase in height and 
thyroid cancer, by sex and cohort 
a Adjusted for age (used as time metric), sex, alcohol intake, physical activity level, race, marital status, education, 
baseline BMI, and smoking status  
b Restricted to height values between 122-244 cm 
NOTE: Weights are from random effects analysis
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Supplementary Figure 2.  Hazard ratios (HRs)a,b and 95% confidence intervals (CIs) for a 5 kg/m2 increase in BMI and 
thyroid cancer, by sex and cohort 
 
a Adjusted for age (used as time metric), sex, alcohol intake, physical activity level, race, marital status, education, and 
smoking status  
b Restricted to BMI values between 15.0-59.9 kg/m2 
NOTE: Weights are from random effects analysis. 
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Supplementary Figure 3.  Hazard ratios (HRs)a,b and 95% confidence intervals (CIs) for a 5 cm increase in waist 
circumference and thyroid cancer, by sex and cohort 
 
a Adjusted for age (used as time metric), sex, alcohol intake, physical activity level, race, marital status, education, and 
smoking status  
b Restricted to waist circumference values between 52-189 cm 
 
 
 
 
NOTE: Weights are from random effects analysis
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Supplementary Figure 4.  Hazard ratios (HRs)a,b and 95% confidence intervals (CIs) for a 5 kg/m2 increase in young-adult 
BMI and thyroid cancer, by sex and cohort 
 
a Adjusted for age (used as time metric), sex, alcohol intake, physical activity level, race, marital status, education, and 
smoking status  
b Restricted to BMI values between 15.0-59.9 kg/m2 
 
 
 
 
 
NOTE: Weights are from random effects analysis
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Supplementary Figure 5.  Hazard ratios (HRs)a and 95% confidence intervals (CIs) for a 5 kg/m2 gain in BMI during 
adulthood and thyroid cancer, by sex and cohort 
a Adjusted for age (used as time metric), sex, alcohol intake, physical activity level, race, marital status, education, 
smoking status, and young-adult BMI (per 5 kg/m2) 
 
NOTE: Weights are from random effects analysis
.
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